Live
- VIP Treatment: Exclusive Benefits for High Rollers in Online Casino
- LS polls: Union Minister Bhagwanth Khuba, Dingaleshwara seer, Priyanka Jarkiholi file nominations in K'taka
- Amid show of strength, Congress’ Praniti Shinde files nomination from Solapur
- Tamil Nadu Police gives clean report to Isha Foundation in missing volunteers case
- Home Minister Amit Shah to address public meeting in Goa on April 24
- Gurgaon Open: M Dharma fires 67 for two-shot lead on penultimate day
- Sharad Pawar made many attempts to finish Shiv Sena, claims Maha minister
- Former England opener Raman Subba Row dies aged 92
- IPL 2024: Impact player rule is affecting the progress of half all-rounders, says Zaheer Khan
- ‘Teppa samudram’ review: Entertains with twists and turns
Optimus Pharma gets DCGI nod for Covid drug
Optimus Pharma gets DCGI nod for Covid drug
City-based Optimus Pharma on Tuesday received DCGI nod for conducting phase III clinical trials for orally administered Molnupiravir capsules on patients with mild and moderate Covid-19.
Hyderabad: City-based Optimus Pharma on Tuesday received DCGI nod for conducting phase III clinical trials for orally administered Molnupiravir capsules on patients with mild and moderate Covid-19. With severe shortage of antiviral drugs in the market against the SARS-CoV-2 infection, it is imperative that more drugs with potent antiviral activity against SARS-CoV-2 be introduced.
Optimus pharma said having internally developed the active pharmaceutical ingredient (API) and the formulations for the product, it had filed for clinical trials with the DCGI.
"Optimus is all geared to immediately begin clinical trials on Molnupiravir on Covid -19 patients in India. The clinical trial will let us know the efficacy of this molecule on Covid patients," CMD Dr D Srinivas Reddy said.
